PABLO PROANO: Open Payments
NPI 1639109036 · SEATTLE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,577 in 167 payments from 15 companies in 2025. Trend: 2023 $13,405 · 2024 $5,831 · 2025 $5,577
Food & beverage: $5,577
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 34 | $1,192 |
| Axsome Therapeutics, Inc. | 13 | $680 |
| Neurocrine BioSciences, Inc. | 13 | $630 |
| Alkermes, Inc. | 14 | $521 |
| ABBVIE INC. | 23 | $499 |
| Teva Pharmaceuticals USA, Inc. | 13 | $443 |
| Vanda Pharmaceuticals Inc. | 9 | $417 |
| E.R. Squibb & Sons, L.L.C. | 7 | $358 |
| Supernus Pharmaceuticals, Inc. | 19 | $306 |
| Otsuka America Pharmaceutical, Inc. | 6 | $213 |
Products named: CAPLYTA, Auvelity, INGREZZA, VRAYLAR, FANAPT, COBENFY, AUSTEDO XR, Qelbree.
Industry payments across WA — which companies pay providers there.
